CL2013000201A1 - Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular. - Google Patents

Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.

Info

Publication number
CL2013000201A1
CL2013000201A1 CL2013000201A CL2013000201A CL2013000201A1 CL 2013000201 A1 CL2013000201 A1 CL 2013000201A1 CL 2013000201 A CL2013000201 A CL 2013000201A CL 2013000201 A CL2013000201 A CL 2013000201A CL 2013000201 A1 CL2013000201 A1 CL 2013000201A1
Authority
CL
Chile
Prior art keywords
antibodies against
activated form
enhanced activated
vertigo
vegetative
Prior art date
Application number
CL2013000201A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of CL2013000201A1 publication Critical patent/CL2013000201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
CL2013000201A 2010-07-21 2013-01-21 Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular. CL2013000201A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера

Publications (1)

Publication Number Publication Date
CL2013000201A1 true CL2013000201A1 (es) 2015-01-23

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000201A CL2013000201A1 (es) 2010-07-21 2013-01-21 Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.

Country Status (23)

Country Link
US (1) US20130058981A1 (OSRAM)
EP (1) EP2596018A2 (OSRAM)
JP (2) JP2013536174A (OSRAM)
KR (1) KR20130102542A (OSRAM)
CN (1) CN103124741A (OSRAM)
AR (1) AR082314A1 (OSRAM)
AU (1) AU2011281248B2 (OSRAM)
BR (1) BR112013001296A2 (OSRAM)
CA (1) CA2805985A1 (OSRAM)
CL (1) CL2013000201A1 (OSRAM)
DE (1) DE112011102397T5 (OSRAM)
EA (1) EA029998B1 (OSRAM)
ES (1) ES2446643R1 (OSRAM)
FR (1) FR2962910A1 (OSRAM)
GB (1) GB2496342B (OSRAM)
IL (1) IL224336A (OSRAM)
IT (1) ITTO20110630A1 (OSRAM)
MX (1) MX355371B (OSRAM)
NZ (1) NZ606988A (OSRAM)
PE (1) PE20131065A1 (OSRAM)
PH (1) PH12013500141A1 (OSRAM)
SG (2) SG10201505676RA (OSRAM)
WO (1) WO2012010974A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
JP2013532182A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
SG187037A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
FR2962912A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer
US20130045237A1 (en) * 2010-08-06 2013-02-21 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
SG187037A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
EP2596019A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
FR2962912A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
US20120258146A1 (en) * 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy

Also Published As

Publication number Publication date
MX2013000805A (es) 2013-10-28
NZ606988A (en) 2015-08-28
WO2012010974A2 (en) 2012-01-26
JP2016199571A (ja) 2016-12-01
FR2962910A1 (fr) 2012-01-27
GB2496342B (en) 2017-12-06
KR20130102542A (ko) 2013-09-17
ES2446643A2 (es) 2014-03-10
WO2012010974A8 (en) 2013-04-25
SG10201505676RA (en) 2015-08-28
ITTO20110630A1 (it) 2012-01-22
JP2013536174A (ja) 2013-09-19
SG187160A1 (en) 2013-02-28
CN103124741A (zh) 2013-05-29
BR112013001296A2 (pt) 2017-12-19
CA2805985A1 (en) 2012-01-26
DE112011102397T5 (de) 2013-05-08
PH12013500141A1 (en) 2013-03-11
IL224336A (en) 2017-06-29
AR082314A1 (es) 2012-11-28
AU2011281248B2 (en) 2017-02-02
PE20131065A1 (es) 2013-09-23
EA029998B1 (ru) 2018-06-29
EP2596018A2 (en) 2013-05-29
GB2496342A (en) 2013-05-08
WO2012010974A3 (en) 2012-04-19
MX355371B (es) 2018-04-17
AU2011281248A1 (en) 2013-03-14
US20130058981A1 (en) 2013-03-07
ES2446643R1 (es) 2015-03-06
EA201300127A1 (ru) 2013-12-30
GB201302925D0 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
DOP2014000084A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
ME03008B (me) Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EP3072536A4 (en) Hydrophilic electrospinning biological composite stent material used for tissue regeneration and preparation method and application thereof
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
EP2888265A4 (en) BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC PROCEDURES THEREWITH
IL235966B (en) Aqueous compositions with a ph level of 6 containing anti-Baffr antibody without fucosylation for use in the treatment of autoimmune diseases
BR112013029187A2 (pt) método e sistema para estabelecimento do formato da cavidade de acesso à oclusão no tratamento endodôntico
CL2013000097A1 (es) Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
BRPI1014027A2 (pt) suspensão de fármaco de nanopartícula estável.
EP2981551A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS POMPE
HRP20190318T1 (hr) Farmaceutski ili kozmetički pripravak za liječenje alopecije
UA107836C2 (uk) Метод лікування хвороби альцгеймера
IL245183B (en) Methods of treating and preventing graft versus host disease
CL2013000202A1 (es) Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique